ERBB2 and breast cancer: Yet, in multivariate analysis (adjusted for tumor size, nodal status and the existence of comorbidities among others) and despite the biological rationale, the current analysis showed no association of statin use on IDFS, DRFI, or OS in this large patient cohort of early HER2 + BC.